{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Guevara M"],"funding":["Fondo Nacional de Innovación y Desarrollo Científico y Tecnológico (FONDOCYT)","Brazilian National Research Council (CNPq)","Instituto de Salud Carlos III (ISCIII) and European Union NextGeneration EU/Plan de Recuperación, Transformación y Resiliencia","AEXCID-Junta de Extremadura"],"pagination":["8"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11768636"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["17(1)"],"pubmed_abstract":["<b>Background/Objectives:</b> Genetic polymorphism of the dihydropyrimidine dehydrogenase gene (<i>DPYD</i>) is responsible for the variability found in the metabolism of fluoropyrimidines such as 5-fluorouracil (5-FU), capecitabine, or tegafur. The <i>DPYD</i> genotype is linked to variability in enzyme activity, 5-FU elimination, and toxicity. Approximately 10-40% of patients treated with fluoropyrimidines develop severe toxicity. The interethnic variability of <i>DPYD</i> gene variants in Afro-Latin Americans is poorly studied, thereby establishing a barrier to the implementation of personalized medicine in these populations. Therefore, the present study aims to analyze the frequency of <i>DPYD</i> variants with clinical relevance in the Dominican population and their association with g"],"journal":["Pharmaceutics"],"pubmed_title":["The Frequency of <i>DPYD</i> c.557A>G in the Dominican Population and Its Association with African Ancestry."],"pmcid":["PMC11768636"],"funding_grant_id":["24IA001","312807/2022-8 and 200824/2024-4","PMP22/00099; BIOFRAM22","2020-201-2C5-204"],"pubmed_authors":["Penas-Lledo E","Rodrigues-Soares F","LLerena A","Manochio C","Dorado P","de la Cruz CG","Rodriguez E","Guevara M"],"additional_accession":[]},"is_claimable":false,"name":"The Frequency of <i>DPYD</i> c.557A>G in the Dominican Population and Its Association with African Ancestry.","description":"<b>Background/Objectives:</b> Genetic polymorphism of the dihydropyrimidine dehydrogenase gene (<i>DPYD</i>) is responsible for the variability found in the metabolism of fluoropyrimidines such as 5-fluorouracil (5-FU), capecitabine, or tegafur. The <i>DPYD</i> genotype is linked to variability in enzyme activity, 5-FU elimination, and toxicity. Approximately 10-40% of patients treated with fluoropyrimidines develop severe toxicity. The interethnic variability of <i>DPYD</i> gene variants in Afro-Latin Americans is poorly studied, thereby establishing a barrier to the implementation of personalized medicine in these populations. Therefore, the present study aims to analyze the frequency of <i>DPYD</i> variants with clinical relevance in the Dominican population and their association with g","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Dec","modification":"2026-04-22T03:25:57.23Z","creation":"2025-04-06T07:44:09.03Z"},"accession":"S-EPMC11768636","cross_references":{"pubmed":["39861660"],"doi":["10.3390/pharmaceutics17010008"]}}